We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
-0.31%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$6.88B
AUM Growth
-$822M
Cap. Flow
-$1.07B
Cap. Flow %
-15.57%
Top 10 Hldgs %
44.23%
Holding
173
New
23
Increased
20
Reduced
28
Closed
33

Top Buys

Rank Stock Value
1
ICVX
Icosavax, Inc. Common Stock
ICVX
+$65.2M
2
PRCT icon
Procept Biorobotics
PRCT
+$63.6M
3
FOLD
Amicus Therapeutics
FOLD
+$35.2M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$32.5M
5
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$31.4M

Top Sells

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$93.6M
2
NVRO
NEVRO CORP.
NVRO
+$73.1M
3
KDMN
Kadmon Holdings, Inc.
KDMN
+$60.8M
4
MDT icon
Medtronic
MDT
+$55.9M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$31.1M

Sector Composition

Rank Sector Weight
1 Healthcare 83.92%
2 Financials 0.85%
3 Industrials 0.17%
4 Consumer Discretionary 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RLAY icon
26
Relay Therapeutics
RLAY
$4B
$61.3M 0.89%
1,943,097
-75,000
-4% -$2.52M
ICVX
27
DELISTED
Icosavax, Inc. Common Stock
ICVX
$56.9M 0.83%
+1,922,549
New +$65.2M
NAUT icon
28
Nautilus Biotechnolgy
NAUT
$132M
$54.7M 0.79%
8,911,151
– –
KRON
29
DELISTED
Kronos Bio
KRON
$50.7M 0.74%
2,421,142
-106,910
-4% -$2.3M
MORF
30
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$50.3M 0.73%
887,340
-50,800
-5% -$3.07M
TVTX icon
31
Travere Therapeutics
TVTX
$5.17B
$47.7M 0.69%
1,965,555
+120,000
+7% +$2.2M
BEAM icon
32
Beam Therapeutics
BEAM
$2.68B
$46.8M 0.68%
537,635
– –
NBIX icon
33
Neurocrine Biosciences
NBIX
$18.2B
$46.3M 0.67%
483,007
-328,825
-41% -$31.1M
VRCA icon
34
Verrica Pharmaceuticals
VRCA
$89M
$45.1M 0.66%
361,041
– –
MGNX icon
35
MacroGenics
MGNX
$233M
$45M 0.65%
2,148,060
– –
KOD icon
36
Kodiak Sciences
KOD
$2.5B
$44.3M 0.64%
461,248
+175,207
+61% +$16.2M
ATNX
37
DELISTED
Athenex, Inc. Common Stock
ATNX
$40.7M 0.59%
676,623
– –
VERU icon
38
Veru
VERU
$35.5M
$38M 0.55%
445,134
– –
RAIN
39
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$38M 0.55%
2,537,019
– –
QTNT
40
DELISTED
Quotient Limited Ordinary Shares
QTNT
$37.9M 0.55%
405,020
– –
DBVT
41
DBV Technologies
DBVT
$813M
$37.7M 0.55%
769,551
– –
INBX
42
DELISTED
Inhibrx, Inc. Common Stock
INBX
$37.4M 0.54%
1,121,490
+214,400
+24% +$6.52M
ESTA icon
43
Establishment Labs
ESTA
$2.71B
$36.2M 0.53%
505,541
-194,867
-28% -$14.4M
OMIC
44
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$34.4M 0.5%
102,461
-301
-0.3% -$154K
CYPH
45
Cypherpunk Technologies Inc
CYPH
$64M
$34M 0.49%
847,650
– –
TMCI icon
46
Treace Medical Concepts
TMCI
$262M
$33.2M 0.48%
1,235,886
– –
CMAX
47
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
$32.7M 0.48%
112,833
+2,166
+2% +$637K
IMTX icon
48
Immatics
IMTX
$1.23B
$32.5M 0.47%
2,500,000
– –
LONA
49
LeonaBio Inc
LONA
$66.1M
$32.1M 0.47%
342,592
– –
SLDB icon
50
Solid Biosciences
SLDB
$792M
$32.1M 0.47%
894,170
– –
1
2
3 4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q3 2021 Portfolio in Review

As of Q3 2021, Perceptive Advisors held 173 positions worth $6.88B, down 11% from $7.71B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Perceptive Advisors withdrew a net $1.07B in Q3 2021, closing 33 positions and reducing 28 holdings. Its most notable exit was Kadmon Holdings, Inc., an estimated $60.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, down from 85% a quarter earlier, followed by Financials and Industrials.

Against the trend, Perceptive Advisors opened a new position in Icosavax, Inc. Common Stock worth $56.9M.

  • Perceptive Advisors's largest Q3 2021 buy was Icosavax, Inc. Common Stock: 1,922,549 shares worth $56.9M.
  • Perceptive Advisors added most to Amicus Therapeutics in Q3 2021, an estimated $35.2M increase.
  • Perceptive Advisors's biggest Q3 2021 reduction was United Therapeutics, cutting an estimated $93.6M.
  • Perceptive Advisors fully exited Kadmon Holdings, Inc. in Q3 2021, selling an estimated $60.8M.
  • Perceptive Advisors's ten largest holdings make up 44% of its $6.88B portfolio in Q3 2021.
  • Perceptive Advisors opened 23 new positions and closed 33 in Q3 2021.
  • Perceptive Advisors's portfolio value fell 11% quarter-over-quarter to $6.88B.

Based on Perceptive Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.